专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090156495A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES 审中-公开
标题翻译：用于调节免疫应答的组合物和方法
公开(公告)号：US20090156495A1
公开(公告)日：2009-06-18
申请号：US12270775
申请日：2008-11-13
申请人： Zeren Gao , Steven D. Levin , Janine Bilsborough , James W. West , Cameron S. Brandt , Frederick J. Ramsdell , Edward D. Howard , Eric M. Chadwick
发明人： Zeren Gao , Steven D. Levin , Janine Bilsborough , James W. West , Cameron S. Brandt , Frederick J. Ramsdell , Edward D. Howard , Eric M. Chadwick
IPC分类号： A61K38/17 , C07K14/47 , C07K19/00
CPC分类号： C07K16/2827 , A61K38/00 , A61K2039/507 , C07K14/47 , C07K14/70532 , C07K16/2803 , C07K16/2818 , C07K2317/34 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/00 , C07K2319/30 , C12Q1/66 , G01N33/505 , G01N33/56972 , G01N2333/70532
摘要： The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
摘要翻译：本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子，并在T细胞上表达。本发明还提供了zB7R1与CD155结合的能力的发现。还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。

2. 发明申请

US20120219540A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES 审中-公开
标题翻译：用于调节免疫应答的组合物和方法
公开(公告)号：US20120219540A1
公开(公告)日：2012-08-30
申请号：US13417587
申请日：2012-03-12
申请人： Zeren Gao , Steven D. Levin , Janine Bilsborough , James W. West , Cameron S. Brandt , Eric M. Chadwick
发明人： Zeren Gao , Steven D. Levin , Janine Bilsborough , James W. West , Cameron S. Brandt , Eric M. Chadwick
IPC分类号： A61K38/17 , G01N33/566 , A61K31/7105 , A61P37/00 , A61K39/395 , A61K31/713
CPC分类号： C07K16/2827 , A61K38/00 , A61K2039/507 , C07K14/47 , C07K14/70532 , C07K16/2803 , C07K16/2818 , C07K2317/34 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/00 , C07K2319/30 , C12Q1/66 , G01N33/505 , G01N33/56972 , G01N2333/70532
摘要： The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1's ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided.
摘要翻译：本发明提供新鉴定的B7受体，作为淋巴细胞抑制性受体的zB7R1，其是PD-1样分子，并在T细胞上表达。本发明还提供了zB7R1与CD155结合的能力的发现。还提供了用于调节zB7R1介导的负信号并干扰其反受体相互作用用于治疗，诊断和研究目的的方法和组合物。

3. 发明授权

US08969518B2 B7 family member zB7H6 and related compositions and methods 有权
标题翻译： B7族成员zB7H6及相关成分及方法
公开(公告)号：US08969518B2
公开(公告)日：2015-03-03
申请号：US12943256
申请日：2010-11-10
申请人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
发明人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
IPC分类号： C07K14/00 , C07K14/705 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译：公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。

4. 发明授权

US07858759B2 Anti-zB7H6 antibody-drug conjugates 有权
标题翻译：抗ZB7H6抗体 - 药物偶联物
公开(公告)号：US07858759B2
公开(公告)日：2010-12-28
申请号：US12246214
申请日：2008-10-06
申请人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao
发明人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao
IPC分类号： C07K16/00
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译：公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。

5. 发明申请

US20090220502A1 B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS 有权
标题翻译： B7家族成员zB7H6及相关组合物和方法
公开(公告)号：US20090220502A1
公开(公告)日：2009-09-03
申请号：US12246214
申请日：2008-10-06
申请人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
发明人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
IPC分类号： A61K39/395 , C07K14/00 , C07H21/00 , C12N15/74 , C12N1/00 , C07K16/18 , A61K38/16 , G01N33/53 , A61P35/00
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译：公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。

6. 发明申请

US20090192291A1 PRODUCTION OF HOMOTRIMERIC FUSION PROTEINS 审中-公开
标题翻译：共培养融合蛋白的生产
公开(公告)号：US20090192291A1
公开(公告)日：2009-07-30
申请号：US12353713
申请日：2009-01-14
申请人： James W. West , Cameron S. Brandt , Stephen R. Jaspers
发明人： James W. West , Cameron S. Brandt , Stephen R. Jaspers
IPC分类号： C07K14/00
CPC分类号： C07K14/47 , C07K14/705 , C07K14/70575 , C07K14/70578 , C07K14/78 , C07K2319/00 , C07K2319/03 , C12N15/62
摘要： The present invention provides method for producing trimeric tumor necrosis factor receptors that are potent inhibitors of their cognate ligands. More particularly, the present invention provides polypeptides that comprise: (1) an extracellular domain of the transmembrane activator and CAML (calcium-signal modulating cyclophilin ligand) interactor (TACI), and (2) a trimerizing polypeptide. Suitable TACI extracellular domains include: (1) amino acid residues 30 to 110 of SEQ ID NO:4, (2) amino acid residues 1 to 110 of SEQ ID NO:4, (3) amino acid residues 30 to 154 of SEQ ID NO:4, and (4) amino acid residues 1 to 154 of SEQ ID NO:4. Illustrative trimerizing polypeptides include a trimerizing fragment of Heat Shock Binding Protein-1. The present invention further provides homotrimeric complexes of fusion proteins comprising a TACI extracellular domain and a trimerizing polypeptide.
摘要翻译：本发明提供了产生三聚体肿瘤坏死因子受体的方法，所述三聚体肿瘤坏死因子受体是其相关配体的有效抑制剂。更具体地，本发明提供多肽，其包含：（1）跨膜激活剂的胞外结构域和CAML（钙信号调节亲环蛋白配体）相互作用体（TACI），和（2）三聚体多肽。合适的TACI细胞外结构域包括：（1）SEQ ID NO：4的氨基酸残基30至110，（2）SEQ ID NO：4的氨基酸残基1至110，（3）SEQ ID NO：4的氨基酸残基30至154 NO.4和（4）SEQ ID NO：4的氨基酸残基1至154。示例性的三聚化多肽包括热休克结合蛋白-1的三聚体片段。本发明还提供了包含TACI胞外域和三聚多肽的融合蛋白的同源三聚体。

7. 发明授权

US08217008B2 Methods of treating inflammatory disease using a soluble IL-20 receptor 有权
标题翻译：使用可溶性IL-20受体治疗炎性疾病的方法
公开(公告)号：US08217008B2
公开(公告)日：2012-07-10
申请号：US12899700
申请日：2010-10-07
申请人： Donald C. Foster , Wenfeng Xu , Karen L. Madden , James D. Kelly , Cindy A. Sprecher , Cameron S. Brandt , Mark W. Rixon , Scott R. Presnell , Brian A. Fox
发明人： Donald C. Foster , Wenfeng Xu , Karen L. Madden , James D. Kelly , Cindy A. Sprecher , Cameron S. Brandt , Mark W. Rixon , Scott R. Presnell , Brian A. Fox
IPC分类号： A61K38/03 , A61K45/00 , C07K14/54 , C12P21/02 , A61P17/00 , C12N15/09 , C12N5/07
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7155 , C07K2319/00
摘要： A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要翻译：具有两个多肽亚单位IL-20RA（以前称为ZcytoR7）和IL-20RB（以前称为DIRS1）的IL-20的可溶性受体。两个亚基优选连接在一起。在一个实施方案中，一个亚基与免疫球蛋白的轻链的恒定区融合，另一个亚基与免疫球蛋白的重链的恒定区融合。轻链和重链通过二硫键连接。

8. 发明申请

US20110171627A1 ZCYTOR19 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS 审中-公开
标题翻译： ZCYTOR19高分子细胞因子受体多核苷酸，多肽，抗体和方法
公开(公告)号：US20110171627A1
公开(公告)日：2011-07-14
申请号：US12723364
申请日：2010-03-12
申请人： Scott R. Presnell , Francis J. Grant , Wenfeng Xu , Stacy Schlutsmeyer , Cameron S. Brandt , Wayne R. Kindsvogel , Katherine E. Henderson , Theodore E. Whitmore , Kevin M. Klucher
发明人： Scott R. Presnell , Francis J. Grant , Wenfeng Xu , Stacy Schlutsmeyer , Cameron S. Brandt , Wayne R. Kindsvogel , Katherine E. Henderson , Theodore E. Whitmore , Kevin M. Klucher
IPC分类号： C12Q1/70 , C07K19/00 , C12N15/63 , C12N1/00 , C12N5/10 , C07K14/715 , G01N33/68
CPC分类号： C07K14/7155
摘要： Novel methods are disclosed for forming a heterodimeric receptor complex with IL-28R and CRF2-4. The methods may be used for detecting and treating viral infections in in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
摘要翻译：公开了与IL-28R和CRF2-4形成异二聚体受体复合物的新方法。该方法可用于体外和体内检测和治疗病毒感染。配体结合受体多肽也可用于在体外和体内阻断配体活性。本发明还包括生产蛋白质的方法，用途及其抗体。

9. 发明授权

US07387780B2 Soluble interleukin-20 receptor 有权
标题翻译：可溶性白介素20受体
公开(公告)号：US07387780B2
公开(公告)日：2008-06-17
申请号：US11458360
申请日：2006-07-18
申请人： Donald C. Foster , Wenfeng Xu , Karen L. Madden , James D. Kelly , Cindy A. Sprecher , Cameron S. Brandt , Mark W. Rixon , Scott R. Presnell , Brian A. Fox
发明人： Donald C. Foster , Wenfeng Xu , Karen L. Madden , James D. Kelly , Cindy A. Sprecher , Cameron S. Brandt , Mark W. Rixon , Scott R. Presnell , Brian A. Fox
IPC分类号： C07K14/705 , C12P21/02
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7155 , C07K2319/00
摘要： A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要翻译：具有两个多肽亚单位IL-20RA（以前称为ZcytoR7）和IL-20RB（以前称为DIRS1）的IL-20的可溶性受体。两个亚基优选连接在一起。在一个实施方案中，一个亚基与免疫球蛋白的轻链的恒定区融合，另一个亚基与免疫球蛋白的重链的恒定区融合。轻链和重链通过二硫键连接。

10. 发明申请

US20100197575A1 SOLUBLE INTERLEUKIN-20 RECEPTOR 审中-公开
标题翻译：可溶性INTERLEUKIN-20受体
公开(公告)号：US20100197575A1
公开(公告)日：2010-08-05
申请号：US12509667
申请日：2009-07-27
申请人： Donald C. Foster , Wenfeng Xu , Karen L. Madden , James D. Kelly , Cindy A. Sprecher , Cameron S. Brandt , Mark W. Rixon , Scott R. Presnell , Brian A. Fox
发明人： Donald C. Foster , Wenfeng Xu , Karen L. Madden , James D. Kelly , Cindy A. Sprecher , Cameron S. Brandt , Mark W. Rixon , Scott R. Presnell , Brian A. Fox
IPC分类号： A61K38/17 , A61P37/06
CPC分类号： C07K16/2866 , A61K38/00 , C07K14/7155 , C07K2319/00
摘要： A soluble receptor to IL-20 having two polypeptide subunits, IL-20RA (formerly called ZcytoR7) and IL-20RB (formerly called DIRS1). The two subunits are preferably linked together. In one embodiment one subunit is fused to the constant region of the light chain of an immunoglobulin, and the other subunit is fused to the constant region of the heavy chain of the immunoglobulin. The light chain and the heavy chain are connected via a disulfide bond.
摘要翻译：具有两个多肽亚单位IL-20RA（以前称为ZcytoR7）和IL-20RB（以前称为DIRS1）的IL-20的可溶性受体。两个亚基优选连接在一起。在一个实施方案中，一个亚基与免疫球蛋白的轻链的恒定区融合，另一个亚基与免疫球蛋白的重链的恒定区融合。轻链和重链通过二硫键连接。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式